Inflation of the TIE as well [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2020-01-29 15:38 (447 d 10:30 ago) – Posting: # 21095
Views: 14,853

Hi Elena,

you are modifying the common decision scheme. Why?
Since you are making essentially the same decisions though in a different order, you gain nothing.

» And another question: is this obligatory to include the detailed description of null and alternative hypotheses for Cmax (ABEL) and AUCt (ABE) together with description of conditions that lead to acceptance/rejection of a hypothesis in a protocol of a full replicate study?

Well, that’s the problem with ABEL (and the FDA’s RSABE as well). There is no Null Hypothesis. Before you assess the data you have no clue which path(s) of the framework you will follow. You can – and should – only describe the procedure.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 13 (0 registered, 13 guests [including 7 identified bots]).
Forum time: Wednesday 03:09 CEST (Europe/Vienna)

In the Middles Ages the lingua franca of science was Latin.
Nowadays the language of science is bad English.    Anonymous

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5